Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Safety Profile in Research 1
Murphy JA, et al
doi: 10.1111/cdd.2016.17.issue-9 7 ShahERezaieARiddleMPimentelM
In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to 14.7% compared to 2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25]
The research is being played out in real-time and in large populations of people who are using the drug for a range of conditions, including off-label uses, Dr
US$ 24.55
US$ 25.69
US$ 29.87
US$ 23.16
US$ 22.35
US$ 23.41
